Anheuser Busch Inbev NV ADR (BUD)vsNovo Nordisk A/S (NVO)
BUD
Anheuser Busch Inbev NV ADR
$68.06
-0.71%
CONSUMER DEFENSIVE · Cap: $133.23B
NVO
Novo Nordisk A/S
$36.33
-1.52%
HEALTHCARE · Cap: $165.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 421% more annual revenue ($309.06B vs $59.32B). NVO leads profitability with a 33.1% profit margin vs 11.5%. BUD appears more attractively valued with a PEG of 1.60. BUD earns a higher WallStSmart Score of 61/100 (C+).
BUD
Buy61
out of 100
Grade: C+
NVO
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.3%
Fair Value
$158.65
Current Price
$68.06
$90.59 discount
Margin of Safety
-59.4%
Fair Value
$24.21
Current Price
$36.33
$12.12 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 63.3% YoY
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 24.9%
Generating 9.9B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 61 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 44.5%
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
4.8% revenue growth
Weak financial health signals
Expensive relative to growth rate
Revenue declined 7.6%
Earnings declined 4.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : BUD
The strongest argument for BUD centers on EPS Growth, Market Cap, Price/Book.
Bull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.
Bear Case : BUD
The primary concerns for BUD are PEG Ratio, Revenue Growth.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
BUD profiles as a value stock while NVO is a declining play — different risk/reward profiles.
BUD carries more volatility with a beta of 0.73 — expect wider price swings.
BUD is growing revenue faster at 4.8% — sustainability is the question.
BUD generates stronger free cash flow (9.9B), providing more financial flexibility.
Bottom Line
BUD scores higher overall (61/100 vs 55/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Anheuser Busch Inbev NV ADR
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other BEVERAGES - BREWERS Stocks
Want to dig deeper into these stocks?